Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study
Li, Jin, Qin, Shukui, Wen, Lu, Wang, Junsheng, Deng, Wenying, Guo, Weijian, Jia, Tongfu, Jiang, Da, Zhang, Guifang, He, Yifu, Ba, Yi, Zhong, Haijun, Wang, Lin, Lin, Xiaoyan, Yang, Jianwei, Zhao, Jun, Bai, Yuxian, Wu, Xiangyuan, Gao, Feng, Sun, Guogui, Wu, Yongjuan, Ye, Feng, Wang, Qiong, Xie, Zhong, Yi, Tienan, Huang, Yong, Yu, Guohua, Lu, Lin, Yuan, Ying, Li, Wei, Liu, Likun, Sun, Yuping, Sun, Ying, Yin, Lifeng, Hou, Zhiguo
Published in BMC medicine (05.05.2023)
Published in BMC medicine (05.05.2023)
Get full text
Journal Article
Quantitative detection of peripheral MDR genes in breast cancer before chemotherapy and their clinical significances
Wang, Xinmei, Li, Liang, Cui, Qing, Wang, Muxin, Ding, Yu, Jia, Tongfu, Li, Jianzhao, Feng, Ningning, Zuo, Anjing, Feng, Yanchang
Published in The Chinese-German journal of clinical oncology (2008)
Published in The Chinese-German journal of clinical oncology (2008)
Get full text
Journal Article
Clinical effectiveness of apatinib at different doses in patients with advanced gastric cancer as the third-line or further treatment: Results from a post-marketing phase IV study
Li, Jin, Qin, Shukui, Wen, Lu, Wang, Junsheng, Deng, Wenying, Guo, Weijian, Jia, Tongfu, Zhao, Qun, Zhang, Guifang, He, Yifu, Zhong, Haijun, Ba, Yi, Lin, Xiaoyan, Yang, Jianwei, Zhao, Jun, Bai, Yuxian, Sun, Guogui, Wu, Yongjuan, Wang, Meng, Sun, Ying
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
Safety and efficacy of apatinib as third or later line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma: A post-marketing phase IV study
Li, Jin, Qin, Shukui, Wen, Lu, Wang, Junsheng, Deng, Wenying, Guo, Weijian, Jia, Tongfu, Jiang, Da, Zhang, Guifang, He, Yifu, Zhong, Haijun, Ba, Yi, Lin, Xiaoyan, Yang, Jianwei, Zhao, Jun, Bai, Yuxian, Wu, Xiangyuan, Gao, Feng, Sun, Ying, Hou, Zhiguo
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
miRNA-148b regulates radioresistance in non-small lung cancer cells via regulation of MutL homologue 1
Zhai, Guangsheng, Li, Gaozhong, Xu, Bo, Jia, Tongfu, Sun, Yinping, Zheng, Jianbo, Li, Jianbin
Published in Bioscience reports (01.07.2016)
Published in Bioscience reports (01.07.2016)
Get full text
Journal Article
Clinical benefit of continuing apatinib beyond progression in advanced or metastatic gastric cancer
Qin, Shukui, Wen, Lu, Wang, Junsheng, Deng, Wenying, Zhang, Guifang, Jia, Tongfu, Ba, Yi, Zhong, Haijun, Yang, Jianwei, Lin, Xiaoyan, Bai, Yu-Xian, He, Yifu, Xie, Zhong, Yi, Tienan, Wu, Xiangyuan, Ye, Feng, Liu, Likun, Huang, Yong, Wang, Mei, Li, Jin
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Impact of time to progression on first-line therapy on clinical outcomes in advanced gastric cancer treated with apatinib: data from a phase IV study (Ahead-G201)
Xie, Zhong, Qin, Shukui, Li, Jin, Wen, Lu, Wang, Junsheng, Deng, Wenying, Zhang, Guifang, Jia, Tongfu, Ba, Yi, Zhong, Haijun, Yang, Jianwei, Lin, Xiaoyan, Bai, Yu-Xian, He, Yifu, Yi, Tienan, Wu, Xiangyuan, Ye, Feng, Liu, Likun, Wang, Mei, Huang, Yong
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Does hypertension history in patients with advanced gastric cancer has an impact on clinical outcomes following apatinib treatment? A subgroup analysis based on data from Ahead-G201 study
Yi, Tienan, Li, Jin, Qin, Shukui, Wen, Lu, Wang, Junsheng, Deng, Wenying, Zhang, Guifang, Jia, Tongfu, Ba, Yi, Zhong, Haijun, Yang, Jianwei, Lin, Xiaoyan, Bai, Yu-Xian, He, Yifu, Xie, Zhong, Wu, Xiangyuan, Ye, Feng, Liu, Likun, Huang, Yong, Wang, Mei
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Safety of apatinib as third-line or beyond treatment in advanced or metastatic gastric cancer: Results from a multicenter phase IV study (Ahead-G201)
Li, Jin, Wen, Lu, Wang, Junsheng, Deng, Wenying, Zhang, Guifang, Jia, Tongfu, Ba, Yi, Zhong, Haijun, Yang, Jianwei, Lin, Xiaoyan, Bai, Yu-Xian, He, Yifu, Xie, Zhong, Yi, Tienan, Wu, Xiangyuan, Ye, Feng, Liu, Likun, Huang, Yong, Wang, Mei, Qin, Shukui
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
BMI differences for clinical outcome in patients with advanced or metastatic gastric cancer treated with apatinib: Data from a post-marketing phase IV study (Ahead-G201)
Bai, Yu-Xian, Qin, Shukui, Li, Jin, Wen, Lu, Wang, Junsheng, Deng, Wenying, Zhang, Guifang, Jia, Tongfu, Ba, Yi, Yang, Jianwei, Lin, Xiaoyan, He, Yifu, Xie, Zhong, Yi, Tienan, Wu, Xiangyuan, Ye, Feng, Liu, Likun, Huang, Yong, Wang, Mei, Zhong, Haijun
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Development of non-hematological adverse events in apatinib-treated gastric cancer and their association with clinical outcome: Results from a phase IV study
Ba, Yi, Li, Jin, Qin, Shukui, Wen, Lu, Deng, Wenying, Zhang, Guifang, Jia, Tongfu, Zhong, Haijun, Yang, Jianwei, Lin, Xiaoyan, Bai, Yu-Xian, He, Yifu, Xie, Zhong, Yi, Tienan, Wu, Xiangyuan, Ye, Feng, Liu, Likun, Huang, Yong, Wang, Mei, Wang, Junsheng
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Effect of ECOG PS on outcome of advanced or metastatic gastric patients treated with apatinib: Analysis from a post-marketing phase IV study
Lin, Xiaoyan, Li, Jin, Qin, Shukui, Wen, Lu, Wang, Junsheng, Deng, Wenying, Jia, Tongfu, Ba, Yi, Zhong, Haijun, Yang, Jianwei, Bai, Yu-Xian, He, Yifu, Xie, Zhong, Yi, Tienan, Wu, Xiangyuan, Ye, Feng, Liu, Likun, Huang, Yong, Wang, Mei, Zhang, Guifang
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Response to apatinib by the number of metastatic organs in patients with advanced or metastatic gastric cancer: Subgroup analysis from a phase IV study (Ahead-G201)
He, Yifu, Li, Jin, Qin, Shukui, Wen, Lu, Wang, Junsheng, Deng, Wenying, Zhang, Guifang, Jia, Tongfu, Ba, Yi, Zhong, Haijun, Yang, Jianwei, Lin, Xiaoyan, Bai, Yu-Xian, Xie, Zhong, Yi, Tienan, Wu, Xiangyuan, Ye, Feng, Huang, Yong, Wang, Mei, Liu, Likun
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Safety and efficacy of apatinib in elderly patients with advanced or metastatic gastric cancer in the post-marketing phase IV study: Subgroup analysis by age (Ahead-G201)
Wen, Lu, Qin, Shukui, Li, Jin, Deng, Wenying, Wang, Junsheng, Zhang, Guifang, Zhong, Haijun, Jia, Tongfu, Ba, Yi, Bai, Yuxian, Lin, Xiaoyan, Wang, Mei, Wang, Lin, Liu, Likun, He, Yifu, Tao, Min, Xie, Congying, Ye, Feng, Wu, Xiang-yuan, Yang, Jianwei
Published in Journal of clinical oncology (01.02.2018)
Published in Journal of clinical oncology (01.02.2018)
Get full text
Journal Article
Effects of apatinib dose interruptions on safety and efficacy in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting
Wang, Junsheng, Qin, Shukui, Li, Jin, Deng, Wenying, Wen, Lu, Zhang, Guifang, Zhong, Haijun, Jia, Tongfu, Yang, Jianwei, Bai, Yuxian, Lin, Xiaoyan, Wang, Mei, Wang, Lin, Liu, Likun, He, Yifu, Tao, Min, Xie, Congying, Ye, Feng, Wu, Xiang-yuan, Ba, Yi
Published in Journal of clinical oncology (01.02.2018)
Published in Journal of clinical oncology (01.02.2018)
Get full text
Journal Article
Effect of region and hospital attribute on outcome of gastric patients treated with apatinib: Data from post-marketing phase IV study
Zhong, Haijun, Qin, Shukui, Li, Jin, Deng, Wenying, Wen, Lu, Wang, Junsheng, Zhang, Guifang, Jia, Tongfu, Yang, Jianwei, Ba, Yi, Bai, Yuxian, Wang, Mei, Wang, Lin, Liu, Likun, He, Yifu, Tao, Min, Xie, Congying, Ye, Feng, Wu, Xiang-yuan, Lin, Xiaoyan
Published in Journal of clinical oncology (01.02.2018)
Published in Journal of clinical oncology (01.02.2018)
Get full text
Journal Article
Association of proteinuria, hypertension, and hand-foot-skin reaction with efficacy of apatinib in gastric cancer: Results from the post-marketing study (Ahead-G201)
Li, Jin, Deng, Wenying, Wen, Lu, Wang, Junsheng, Zhang, Guifang, Zhong, Haijun, Jia, Tongfu, Yang, Jianwei, Ba, Yi, Bai, Yuxian, Lin, Xiaoyan, Wang, Mei, Wang, Lin, Liu, Likun, He, Yifu, Tao, Min, Xie, Congying, Ye, Feng, Wu, Xiang-yuan, Qin, Shukui
Published in Journal of clinical oncology (01.02.2018)
Published in Journal of clinical oncology (01.02.2018)
Get full text
Journal Article
Initial dose of apatinib in Chinese patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting: 500 mg or 850 mg?
Deng, Wenying, Qin, Shukui, Li, Jin, Wen, Lu, Wang, Junsheng, Zhang, Guifang, Zhong, Haijun, Yang, Jianwei, Ba, Yi, Bai, Yuxian, Lin, Xiaoyan, Wang, Mei, Wang, Lin, Liu, Likun, He, Yifu, Tao, Min, Xie, Congying, Ye, Feng, Wu, Xiang-yuan, Jia, Tongfu
Published in Journal of clinical oncology (01.02.2018)
Published in Journal of clinical oncology (01.02.2018)
Get full text
Journal Article
Comparisons between intestinal and diffuse gastric cancer in response to apatinib: Data from post-marketing phase IV study
Zhang, Guifang, Qin, Shukui, Li, Jin, Deng, Wenying, Wen, Lu, Wang, Junsheng, Zhong, Haijun, Jia, Tongfu, Yang, Jianwei, Ba, Yi, Lin, Xiaoyan, Wang, Mei, Wang, Lin, Liu, Likun, He, Yifu, Tao, Min, Xie, Congying, Ye, Feng, Wu, Xiang-yuan, Bai, Yuxian
Published in Journal of clinical oncology (01.02.2018)
Published in Journal of clinical oncology (01.02.2018)
Get full text
Journal Article
Apatinib as third-line or beyond therapy in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction: An open-label, multicenter, post-marketing phase IV study (Ahead-G201)
Qin, Shukui, Deng, Wenying, Wen, Lu, Wang, Junsheng, Zhang, Guifang, Zhong, Haijun, Jia, Tongfu, Yang, Jianwei, Ba, Yi, Bai, Yuxian, Lin, Xiaoyan, Wang, Mei, Wang, Lin, Liu, Likun, He, Yifu, Tao, Min, Xie, Congying, Ye, Feng, Wu, Xiang-yuan, Li, Jin
Published in Journal of clinical oncology (01.02.2018)
Published in Journal of clinical oncology (01.02.2018)
Get full text
Journal Article